Impaired hippocampal circuit function underlying memory encoding and consolidation precede robust Aβ deposition in a mouse model of alzheimer's disease
- PMID: 40594747
- PMCID: PMC12217341
- DOI: 10.1038/s41598-025-05653-2
Impaired hippocampal circuit function underlying memory encoding and consolidation precede robust Aβ deposition in a mouse model of alzheimer's disease
Abstract
Current therapeutic strategies for Alzheimer's disease (AD) target amyloid-beta (Aβ) fibrils and high molecular weight protofibrils associated with plaques, but molecular cascades associated with AD may drive neural systems failure before Aβ plaque deposition in AD. Employing hippocampal electrophysiological recordings and dynamic calcium imaging across the sleep-wake cycle in a freely behaving mouse model of AD before Aβ plaques accumulated, we detected marked impairments of hippocampal systems function: In a spatial behavioral task, phase-amplitude coupling (PAC) of the hippocampal theta and gamma oscillations was impaired and place cell calcium fluctuations were hyper-synchronized with the theta oscillation. These changes were not observed in REM sleep. In subsequent slow wave sleep (SWS), place cell reactivation was reduced. These degraded neural functions underlying memory encoding and consolidation support targeting pathological processes of the pre-plaque phase of AD to treat and prevent hippocampal impairments.
Keywords: Alzheimer’s disease; Amyloid-beta; Electrophysiology; Hippocampus; Place cell; Sleep.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Competing interests: The authors declare no competing interests.
Figures
Update of
-
Impaired hippocampal circuit function underlying memory encoding and consolidation precede robust Aβ deposition in a mouse model of Alzheimer's disease.bioRxiv [Preprint]. 2025 Apr 19:2024.05.26.595168. doi: 10.1101/2024.05.26.595168. bioRxiv. 2025. Update in: Sci Rep. 2025 Jul 1;15(1):21957. doi: 10.1038/s41598-025-05653-2. PMID: 38853978 Free PMC article. Updated. Preprint.
References
-
- Bloom, G. S. Amyloid-β and tau: the trigger and bullet in alzheimer disease pathogenesis. JAMA Neurol.71, 505–508 (2014). - PubMed
-
- van Dyck, C. H. et al. Lecanemab in early alzheimer’s disease. N. Engl. J. Med.388, 9–21 (2023). - PubMed
-
- Mintun, M. A. et al. Donanemab in early alzheimer’s disease. N Engl. J. Med.384, 1691–1704 (2021). - PubMed
-
- Budd Haeberlein, S. et al. Two randomized phase 3 studies of aducanumab in early alzheimer’s disease. J. Prev. Alzheimers Dis.9, 197–210 (2022). - PubMed
-
- Honig, L. S. et al. Trial of Solanezumab for mild dementia due to alzheimer’s disease. N Engl. J. Med.378, 321–330 (2018). - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
